PS-Pomalidomide REMS

Prescriber Enrollment Form

All prescribers must be certified to prescribe pomalidomide. To become certified the prescriber must:

- 1. Complete the Prescriber Enrollment Form, which is required for PS-Pomalidomide REMS certification.
- 2. Agree to steps on the following page that must be followed with every patient.

To submit this form electronically, please visit www.BMSREMSPatientSafety.com/prescriber.

To submit this form via fax, please complete the following page and fax it to 1-888-432-9325.

Pomalidomide is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with pomalidomide provided adequate precautions are taken to avoid pregnancy.

Please review the steps on the following page that must be followed with every patient.

The PS-Pomalidomide REMS includes both POMALYST® (pomalidomide) and generic pomalidomide products. The pomalidomide manufacturers have a contractual agreement for administration of the PS-Pomalidomide REMS. All manufacturers retain responsibility for the actions described in the REMS.

PS-Pomalidomide REMS Prescriber Enrollment Form

When prescribing pomalidomide, I agree to:

- Provide patient counseling on the benefits and risks of pomalidomide therapy, including Boxed Warnings
- Submit a completed PS-Pomalidomide REMS Patient-Physician Agreement Form for each new patient
- Provide contraception and emergency contraception counseling with each new prescription prior to and during pomalidomide treatment
- Provide scheduled pregnancy testing for females of reproductive potential and verify negative pregnancy test results prior to writing a new prescription or subsequent prescriptions
- Report any pregnancies in female patients or female partners of male patients prescribed pomalidomide immediately to PS-Pomalidomide REMS
- Complete a mandatory and confidential <u>prescriber</u> survey online or by telephone for all patients and obtain a new
 authorization number for each prescription written. The authorization number and patient risk category must then be
 written on each prescription
- Facilitate female patient compliance with an initial mandatory confidential patient survey online or by telephone
- Prescribe no more than a 4-week (28-day) supply, with no automatic refills or telephone prescriptions
- Contact a PS-Pomalidomide REMS certified pharmacy to fill the prescription
- Remind patients to return all pomalidomide capsules to PS-Pomalidomide REMS or their pomalidomide prescriber, or to the pharmacy that dispensed the pomalidomide to them
- Return to PS-Pomalidomide REMS all pomalidomide capsules that are returned by patients. Shipping fees will be paid by PS-Pomalidomide REMS. To arrange returns, call the REMS Call Center at 1-888-423-5436
- Re-enroll patients in the PS-Pomalidomide REMS program if pomalidomide is required and previous therapy with pomalidomide has been discontinued for 12 consecutive months

Please fill out the spaces below c	ompletely.		
Prescriber Name			
Degree: MD/DO/PA/NP/Fellow/Med	ical Resident		
Specialty			
Prescriber Identification Number (eg	, DEA Number, Social Security Numb	oer, NPI Number, etc.)	
Please indicate which office(s) will	Il receive PS-Pomalidomide REMS	materials and updates:	
☐ Primary Office Name			
Attention			
		ZIP Code	
Phone	Ext	Fax	
Email Address			
City	State	ZIP Code	
Phone	Ext	Fax	
Email Address			
		ilidomide REMS, my prescriptions for pomali	
Prescriber Signature		Date	

Return this form to the REMS Call Center via fax.

REMS Call Center Phone: **1-888-423-5436** Fax: **1-888-432-9325**

www.BMSREMSPatientSafety.com

PS-Pomalidomide REMS